A randomized, double-blind, placebo-controlled, dose ascending, 3-cohort parallel group study to measure the systemic cortisol profile and evaluate the safety, tolerability and pharmacokinetics of GW870086X[GSK-870086], administered as single doses (12mg and 15mg), and repeat doses over 3 days (6mg, 12mg and 15mg) in healthy male subjects.

Trial Profile

A randomized, double-blind, placebo-controlled, dose ascending, 3-cohort parallel group study to measure the systemic cortisol profile and evaluate the safety, tolerability and pharmacokinetics of GW870086X[GSK-870086], administered as single doses (12mg and 15mg), and repeat doses over 3 days (6mg, 12mg and 15mg) in healthy male subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs GSK 870086 (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Oct 2008 Actual start date changed from Oct 2007 to Sep 2007 as reported by Clinicaltrials.gov
    • 31 Mar 2008 Status change from initiated to completed according to clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top